Golden
Neos Therapeutics

Neos Therapeutics

Neos Therapeutics is a pharmaceutical company developing ADHD medications.

Neos Therapeutics is a biopharmaceutical company developing, manufacturing, and commercializing extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms. Its area of focus is the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Products

Adzenys XR-ODT, Contempla XR-ODT, and Adzenys ER

The company has three approved products for the treatment of ADHD in the market, Adzenys XR-ODT, Contempla XR-ODT, and Adzenys ER. Adzenys XR-ODT and Adzenys ER are central nervous system (CNS) stimulant prescription medicines used for the treatment of ADH in people 6 years of age and above.  Contempla XR-ODT on the other hand, is for children aged 6 to 17 years old.

Tussionex

Neos also has the commercialization and profit rights to Generic Tussionex (Extended Release Hydrocodone Polistired/Chlorpheniramine Polistirex) from its collaboration partners, Chiesi USA and Coating Place. The product is indicated for the relief of cough and upper respiratory symptoms associated with allergy or colds in adults and children six years of age and above. 

NT0400 and NR0501

In its product pipeline, Neos has NT0400 and NR0501, which are treatments for nausea & vomitting and sialorrhea (excessive drooling), respectively. Both products are in the pre-clinical stages.

Funding

Venture

On June 9, 2011 Neos Therapeutics completed a venture capital round with $13.6 million in funding from undisclosed investors. 

Series B

On November 24, 2009 Neos Therapeutics completed their series B funding round with $24.1 million in funding from undisclosed investors. 

Series C

On March 4, 2014 Neos Therapeutics completed their series C funding round with $15.5 million in funding from Delaware Street Capital, Cabtree Partners, SMEA Capital, and Birrill & Company. 

Timeline

March 31, 2019

Venture funding round

On June 9, 2011 Neos Therapeutics completed a venture capital round with $13.6 million in funding from undisclosed investors. 

March 4, 2014

Series C funding round

On March 4, 2014 Neos Therapeutics completed their series C funding round with $15.5 million in funding from Delaware Street Capital, Cabtree Partners, SMEA Capital, and Birrill & Company. 

December 24, 2009

Series B funding round

On November 24, 2009 Neos Therapeutics completed their series B funding round with $24.1 million in funding from undisclos

Funding rounds

1 Result
Funding round
Funding round
Funding round amount (USD)
Funding round amount (USD)
Funding type
Funding type
Funding round date
Funding round date
Investment
Investment

People

Name
Role
LinkedIn

Amy Revello

Employee



Asif Mughal

VP of Quality Assurance



Carolyn Sikes

VP of Clinical Affairs



Dorothy Engelking

VP of Regulatory Affairs



Georgianne M Russ

Employee



Jerry McLaughlin

Director & CEO



Margaret Cabano

VP of Operations



Richard Eisenstadt

CFO



Russ McMahen

Senior VP of Research & Development



Sharon Kopp

Employee



Steven Lutz

VP of Trade Sales



Further reading

Title
Author
Link
Type
Date

Neos Therapeutics Acquires all Commercialization and Profit Rights to Generic Tussionex® (Extended Release Hydrocodone Polistirex/Chlorpheniramine Polistirex) from Chiesi USA and Coating Place, Inc.

Business Wire

Web



Neos Therapeutics Announces Realignment of Commercial Organization

Neos Therapeutics

Web



Neos Therapeutics Announces Settlement with Teva on Cotempla XR-ODT® Patent Litigation

Neos Therapeutics

Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References